Moderate to severe allergic asthma
Conditions
Interventions
Omalizumab treatment group:Nil
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
6 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 6-18 years, no gender limit; 2. The diagnosis of asthma complies with the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Chinese Children (2016 Edition), and those who can achieve complete control after the third-level asthma drug treatment are moderate asthma; severe asthma can be achieved by the 4th or 5th grade asthma drug treatment, or can not be completely controlled by the above treatment; 3. Adenoid hypertrophy and (or) OSAS can be diagnosed at the same time; 4. It can be diagnosed as allergic rhinitis at the same time; 5. Positive allergen test: positive serum total IgE, skin prick test or specific IgE (sIgE); 6. All the children received conventional treatment with inhaled glucocorticoid + long-acting bronchodilator, and the control was not good for >=3 months; 7. Receive omalizumab during outpatient or hospitalization.
Exclusion criteria
Exclusion criteria: Participate in clinical trials of other treatment studies during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laboratory test results;Pulmonary function and diastolic test results;FeNO test results;Asthma Quality of Life Questionnaire;OSAS-related testing and scoring results;Allergic rhinitis related test results;Adverse reactions; | — |
Countries
China
Contacts
Public ContactYe Leping
Peking University First Hospital
Outcome results
None listed